Compare PSEC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | ALVO |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | Luxembourg |
| Employees | 8 | 1460 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | PSEC | ALVO |
|---|---|---|
| Price | $2.34 | $3.79 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 4.5M | 785.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 20.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $2.94 |
| 52 Week High | $3.13 | $9.25 |
| Indicator | PSEC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 57.03 |
| Support Level | $2.15 | $3.10 |
| Resistance Level | $2.35 | $4.02 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 50.11 | 70.37 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.